Irinotecan Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a topoisomerase I inhibitor presented as an injection solution for intravenous use. It is indicated for the treatment of metastatic colorectal cancer in adult patients and is approved in the European Union market.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides cold‑chain logistics where required. Clients benefit from reliable delivery timelines and regulatory support for importation.

Irinotecan Kabi is used in colorectal cancer treatment regimens that target tumor cell proliferation.

- Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based chemotherapy. - Refractory colorectal cancer: provides clinical benefit in patients whose disease has progressed after first‑line therapy. - Advanced colorectal cancer (first‑line): forms part of the standard FOLFIRI regimen to reduce tumor burden.

Irinotecan Kabi may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Diarrhea, which can be severe - Neutropenia and leukopenia - Alopecia (hair loss) - Fatigue and weakness - Decreased appetite

Serious or Rare Side Effects: - Febrile neutropenia or severe bone‑marrow suppression - Life‑threatening colitis or severe diarrhea - Hepatic toxicity with elevated transaminases - Hypersensitivity reactions including anaphylaxis - Pulmonary toxicity such as interstitial pneumonitis - Severe electrolyte disturbances

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for toxicity.

- Dose adjustment: required in patients with hepatic impairment. - Baseline labs: obtain complete blood count and liver function tests prior to each cycle. - Diarrhea management: initiate antidiarrheal prophylaxis and monitor fluid balance. - Myelosuppression: monitor neutrophil counts and consider growth‑factor support if needed. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) markedly reduce irinotecan exposure. - UGT1A1 inhibitors (e.g., atazanavir) can increase SN‑38 levels and raise risk of severe neutropenia. - Concurrent myelosuppressive agents may cause profound bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs may exacerbate irinotecan‑induced diarrhea. - Anticoagulants can increase bleeding risk when hepatic function is compromised. - Moderate CYP3A4 inhibitors (e.g., ketoconazole) may raise plasma concentrations, requiring dose adjustment.